These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 22421702)
1. Amantadine-induced myoclonus in a patient with progressive supranuclear palsy. Yarnall AJ; Burn DJ Age Ageing; 2012 Sep; 41(5):695-6. PubMed ID: 22421702 [TBL] [Abstract][Full Text] [Related]
2. [Treatment of progressive supranuclear palsy]. Finali G; Piccinin GL; Piccirilli M; Stefano E Clin Ter; 1989 Jun; 129(5):339-51. PubMed ID: 2569956 [TBL] [Abstract][Full Text] [Related]
3. Treatment of progressive supranuclear palsy and corticobasal degeneration. Lang AE Mov Disord; 2005 Aug; 20 Suppl 12():S83-91. PubMed ID: 16092096 [TBL] [Abstract][Full Text] [Related]
4. Pathological hypersexuality induced by dopamine replacement therapy in a patient with progressive supranuclear palsy. Kim YY; Park HY; Kim JM; Kim KW J Neuropsychiatry Clin Neurosci; 2008; 20(4):496-7. PubMed ID: 19196941 [No Abstract] [Full Text] [Related]
5. A Review of Treatment Options for Progressive Supranuclear Palsy. Stamelou M; Höglinger G CNS Drugs; 2016 Jul; 30(7):629-36. PubMed ID: 27222018 [TBL] [Abstract][Full Text] [Related]
6. [Edemas and myocloni concerning a patient with Parkinson's disease treated by amantadine (author's transl)]. Chevalier JF; Renier E; Brion S Encephale; 1980; 6(4):381-4. PubMed ID: 7439114 [TBL] [Abstract][Full Text] [Related]
7. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. O'Sullivan SS; Djamshidian A; Ahmed Z; Evans AH; Lawrence AD; Holton JL; Revesz T; Lees AJ Mov Disord; 2010 Apr; 25(5):638-42. PubMed ID: 20213825 [TBL] [Abstract][Full Text] [Related]
8. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Birdi S; Rajput AH; Fenton M; Donat JR; Rozdilsky B; Robinson C; Macaulay R; George D Mov Disord; 2002 Nov; 17(6):1255-64. PubMed ID: 12465065 [TBL] [Abstract][Full Text] [Related]
9. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734 [TBL] [Abstract][Full Text] [Related]
10. [Descriptive study of a serie of patients affected by progressive supranuclear palsy]. Villanueva-Haba VE; Garcés M; de Vera A; Valero C; Burguera JA Rev Neurol; 2001 Jun 1-15; 32(11):1027-30. PubMed ID: 11562823 [TBL] [Abstract][Full Text] [Related]
11. [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient]. Ceballos-Baumann AO MMW Fortschr Med; 2002 May; Suppl 2():37-43. PubMed ID: 12070848 [TBL] [Abstract][Full Text] [Related]
17. [An autopsy case of progressive supranuclear palsy with olivary hypertrophy]. Takeuchi M; Sasaki S; Ito A; Osawa M; Kobayashi I; Maruyama S No To Shinkei; 1991 Sep; 43(9):863-7. PubMed ID: 1742094 [TBL] [Abstract][Full Text] [Related]
18. Subthalamic stimulation improves levodopa responsive symptoms in a case of progressive supranuclear palsy. Bergmann KJ; Salak VL Parkinsonism Relat Disord; 2008; 14(4):348-52. PubMed ID: 17825599 [TBL] [Abstract][Full Text] [Related]